Ying Song

Ying Song

Auto-generated profile, based on publicly available information

Ying Song

Department of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases, the First Affiliated Hospital of Chongqing Medical University, China (Q. Liu, S.Z., L.M., J.F., J.C., M.C., Y. Yu, F.H., C.P., Y.W., Y.S., Y.J., H.S., W.L., Y. Yang, J.H., Q. Li, S.Y.).

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Circulation
Verified
Journal Article
Closed access
JHJinbo Hu
Jinbo Hu
QZQixin Zhou
Qixin Zhou
YSYue Sun
Yue Sun
ZFZhengping Feng
Zhengping Feng
JYJun Yang
Jun Yang
CGCONPASS Group
CONPASS Group

1 September 2013 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
QCQingfeng Cheng
Qingfeng Cheng
WXW. Xia
W. Xia
SYShumin Yang
Shumin Yang
PYP. Ye
P. Ye
MMM. Mei
M. Mei
QLQifu Li
Qifu Li

18 June 2021 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
TZTang Ziwei
Tang Ziwei
QLQifu Li
Qifu Li
QCQingfeng Cheng
Qingfeng Cheng
MMMei Mei
Mei Mei
YSYing Song
Ying Song
ZWZhihong Wang
Zhihong Wang
Objective. It has been increasingly appreciated that G protein-coupled estrogen receptor 1 (GPER1) mediates both proinflammatory and anti-inflammatory response of estrogen. It is also involved in some rapid vascular effects of aldosterone in a mineralocorticoid receptor (MR) independent manner. However, whether GPER1 mediates aldosterone-induced inflammation response in endothelial cells and its relationship with MR are yet undetermined and therefore require further explanation. Method. Based on the hypothesis that GPER1 plays a role in the aldosterone-related vascular inflammation, the present study utilized a model of human umbilical vein endothelial cells transfected with MR siRNA and induced for inflammatory response with increasing concentration of aldosterone. Results. It was discovered that induction of aldosterone had no effect on the expression of GPER1 but promoted the expression of MR. Suppression of MR did not influence GPER1 expression, and GPER1 was capable of mediating part of aldosterone-induced endothelial inflammatory response. This effect may involve phosphoinositide 3-kinases (PI3K) pathway signaling. Conclusion. These findings not only demonstrated the role of GPER1 in aldosterone-induced vascular inflammation but also suggested an alternative for pharmaceutical treatment of hyperaldosteronism considering the unsatisfying effect on cardiovascular risks with MR antagonists.

1 September 2026 in Hypertension
Verified
Journal Article
Closed access
JYJun Yang
Jun Yang
JGJessica Goi
Jessica Goi
Jacopo BurrelloJacopo Burrello
Jacopo Burrello
MPMartin Reincke Prof
Martin Reincke Prof
CAChristian Adolf
Christian Adolf
PFPeter J. Fuller
Peter J. Fuller
BACKGROUND: Primary aldosteronism (PA) is a common and treatable cause of hypertension, yet data on the durability of medical treatment response beyond the first year are limited. Using the PA medical treatment outcomes framework, we evaluated long-term biochemical and clinical outcomes and factors associated with treatment response. METHODS: We conducted an international, multicenter, observational cohort study across 27 centers on 4 continents. Adults with PA treated with mineralocorticoid receptor antagonists and/or epithelial sodium channel blockers between 2016 and 2021 were included if follow-up data were available at ≥12 months. Biochemical and clinical responses were classified as complete, partial, or absent using PA medical treatment outcomes criteria. Ordinal logistic regression identified determinants of a favorable treatment response. RESULTS: The cohort included 1292 patients (47.5% women, mean age 52 years) with a median follow-up of 34 months (interquartile range, 21–51). At ≥12 months, 58.3% achieved a complete biochemical response, and 20.8% achieved a complete clinical response, with only 5% showing no response. Determinants of a favorable biochemical response included lower aldosterone and lateralization index, and higher renin and potassium levels at baseline. In those taking spironolactone, a higher daily dose was also associated with a favorable biochemical response. Determinants of a favorable clinical response included female sex, lower body mass index, shorter duration of hypertension, and absence of hypertension-mediated organ damage. CONCLUSIONS: Targeted medical therapy for PA can deliver sustained biochemical and clinical benefits. Early disease detection and adequate dose titration are highly actionable determinants of long-term treatment success.

1 May 2026 in Hypertension
Verified
Journal Article
Closed access
MLMansi Luo
Mansi Luo
LMLinqiang Ma
Linqiang Ma
XWXiao Wang
Xiao Wang
YYYixuan Yu
Yixuan Yu
JHJinbo Hu
Jinbo Hu
YJYing Jing
Ying Jing
BACKGROUND: Aldosterone-producing adenoma is a major cause of primary aldosteronism. However, the molecular mechanisms underlying aldosterone overproduction remain incompletely understood. The expression of peptide deformylase, which is essential for the maturation of mitochondrially encoded proteins, was significantly upregulated in our previous proteomic analysis. We aimed to elucidate the role of peptide deformylase in aldosterone overproduction. METHODS: Peptide deformylase expression was validated in enlarged aldosterone-producing adenoma samples harboring different mutations and in adrenocortical cell lines. A key protein exhibiting the most significant change was identified through proteomic analysis of peptide deformylase-knockdown cells and validated in vitro. RESULTS: Both peptide deformylase expression and aldosterone synthase (CYP11B2 [cytochrome P450 family 11 subfamily B member 2]) colocalization were significantly enhanced in aldosterone-producing adenoma samples. Among the 43 genotyped cases, peptide deformylase upregulation was most pronounced in KCNJ5 - and ATP1A1 -mutant tumors, and its expression was positively correlated with CYP11B2 expression, plasma aldosterone levels, and the aldosterone-to-renin ratio. In H295R cell (human adrenocortical carcinoma cell line, NCI-H295R cell), peptide deformylase overexpression increased aldosterone production, whereas peptide knockdown inhibited aldosterone production. Furthermore, proteomic analysis revealed that peptide deformylase deficiency significantly upregulated the expression of CALB1 (calbindin 1), which is a key cytosolic calcium-buffering protein. Additional data highlighted the CALB1-calcium axis as a key regulator of CYP11B2 expression and aldosterone production and showed that peptide deformylase may modulate CALB1 expression through TBX2 (T-box transcription factor 2)–dependent transcriptional regulation. CONCLUSIONS: Peptide deformylase regulates CYP11B2 expression and aldosterone production. The CALB1-calcium signaling pathway may mediate the effects of peptide deformylase on aldosterone overproduction.

1 January 2022 in Journal of Geriatric Cardiology
Verified
Journal Article
Closed access
NXNa Xu
Na Xu
CZCe Zhang
Ce Zhang
LJLin Jiang
Lin Jiang
JXJing-Jing Xu
Jing-Jing Xu
RLRu Liu
Ru Liu
LSLei Song
Lei Song
To determine whether high-risk patients with three-vessel disease (TVD) with and without prior stroke preferentially benefit from three strategies [percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) and medical therapy (MT)]. A total of 8943 patients with TVD were included in the study. Patients enrolled were stratified into two categories according to the presence or absence of prior stroke history. The primary endpoint was all-cause death. Secondary endpoints included stroke and major adverse cardiac and cerebrovascular event (MACCE), a composite of death, myocardial infarction (MI), unplanned revascularization and stroke. Prior stroke was present in 888 patients (9.9%). These patients were older and had higher rates of comorbidities. During a median follow-up of 7.5 years, patients with prior stroke were strongly associated with increased risks of all-cause death, cardiac death, stroke and MACCE, even after adjusting for confounding variables and results been consistent across either treatment subgroup (PCI, CABG and MT) (all adjusted P < 0.01). Notably, there was a significant interaction between prior stroke history and treatment strategies. Revascularization strategy (PCI or CABG) was associated with a lower incidence of all-cause death and MACCE compared with MT alone, and favorable rates of MACCE, MI and unplanned revascularization in the CABG group compared with the PCI group, but with similar rate of all-cause death regardless of prior stroke history. The prevalence of stroke was significantly higher after CABG when compared with PCI or MT in no prior stroke patients [hazard ratio (HR) = 1.429, 95% CI: 1.132–1.805 for CABG vs. MT; HR = 1.703, 95% CI: 1.371–2.116 for CABG vs. PCI]. Patients with TVD and prior stroke have poor clinical outcomes. It is essential to balance benefit and risk when determining the optimal treatment strategy for TVD with and without prior stroke.